Ensign Peak Advisors, Inc Zai Lab LTD Transaction History

Ensign Peak Advisors, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$30.21 - $48.1 $78,546 - $125,060	2,600 Added 41.27%	8,900 $296,000
Q4 2022 Feb 13, 2023	BUY	$22.28 - $38.71 $10,026 - $17,419	450 Added 7.69%	6,300 $193,000
Q3 2022 Nov 14, 2022	BUY	$34.2 - $51.69 $13,680 - $20,676	400 Added 7.34%	5,850 $200,000
Q2 2021 Aug 13, 2021	BUY	$125.11 - $180.0 $93,832 - $135,000	750 Added 15.96%	5,450 $965,000
Q1 2021 May 12, 2021	BUY	$126.27 - $191.71 $441,945 - $670,985	3,500 Added 291.67%	4,700 $627,000
Q4 2020 Feb 12, 2021	BUY	$81.94 - $135.34 $98,328 - $162,408	1,200 New	1,200 $162,000

125

49.6M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.72B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.